TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03328403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspiration First
Description: Use aspiration system (mainly Penumbra) first, other devices would be used if the first device failed to open the occluded vessel satisfactorily, depending on clinical situation and the involved interventionists' preferences.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent retriever first
Description: Use one of the stent retrievers (Trevo / Solitaire) first, other devices would be used if the first device failed to open the occluded vessel satisfactorily, depending on clinical situation and the involved interventionists' preferences.
Study: NCT00104559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iMIC-generated consent form and tutorial
Description: Computer-based consent form and tutorial

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iMIC-generated consent form and tutorial
Description: Computer-based consent form and tutorial

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iMIC-generated consent form and tutorial
Description: Computer-based consent form and tutorial

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iMIC-generated consent form and tutorial
Description: Computer-based consent form and tutorial

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard paper consent form
Description: Standard paper consent form

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard paper consent form
Description: Standard paper consent form

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard paper consent form
Description: Standard paper consent form

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard paper consent form
Description: Standard paper consent form
Study: NCT04259073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: two capsules, one is placebo, the other correspond to pregabalin 150 mg ingested orally one hour before cesarean section

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: two capsules filled with sugar ingested orally one hour before cesarean section

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 300mg
Description: two capsules of pregabalin 150 mg ingested orally one hour before cesarean section
Study: NCT01049971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wound protector
Description: after minilaparotomy, the wound protector is applied

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: no wound protector
Description: use of woven drape instead of wound protector
Study: NCT03434782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In-office dental bleaching
Description: The group will receive in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 3 sessions, with a 7-day interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In-office dental bleaching
Description: The group will receive in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 3 sessions, with a 7-day interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In-office dental bleaching
Description: The group will receive in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 3 sessions, with a 7-day interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In-office dental bleaching
Description: The group will receive in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 3 sessions, with a 7-day interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: It will be used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and apical region of the incisors, canines and premolars.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: It will be used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and apical region of the incisors, canines and premolars.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% potassium nitrate / 2% sodium fluoride gel
Description: 5% potassium nitrate / 2% sodium fluoride gel will be applied for 10 minutes on the vestibular surface of all pre-bleached dental elements, following the manufacturer's protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% potassium nitrate / 2% sodium fluoride gel
Description: 5% potassium nitrate / 2% sodium fluoride gel will be applied for 10 minutes on the vestibular surface of all pre-bleached dental elements, following the manufacturer's protocol.
Study: NCT04643288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open flap debridement
Description: open flap debridement for managing two and three walls intrabony periodontal defects

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open flap debridement
Description: open flap debridement for managing two and three walls intrabony periodontal defects

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: n-HA bone graft
Description: Nanocrystalline Hydroxyapatite bone graft substitute for managing two and three walls intrabony periodontal defects
Study: NCT00521560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin
Description: All applications of 90Y-Ibritumomab-Tiuxetan will be preceded by rituximab infusions at a dose of 250 mg/m2 at days -21 and day -14 (DL1) or day -12 (DL2) or day -10 (DL3-5), respectively.~High dose therapy will be given as BEAM
Study: NCT00648817

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir DF placebo
Description: Tenofovir DF placebo tablet QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir DF placebo
Description: Tenofovir DF placebo tablet QD
Study: NCT04328636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Magnesium Sulfate
Description: Nebulized magnesium sulfate (isotonic solution) 256 mg every 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Magnesium Sulfate
Description: Intravenous magnesium sulfate 200 mg/kg over 30 minutes, followed by a continuous infusion at a rate of 50 mg/kg/hour
Study: NCT04564651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: platelet transfusion
Description: when the ADP inhibition \>70%, give one unit platelet tansfusion
Study: NCT01259726

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VP20621
Description: VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for seven days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VP20621
Description: VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for 7 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mL placebo once daily for 14 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 10 mL placebo once daily for 14 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 10 mL placebo once daily for 14 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VP20621
Description: VP20621 as oral liquid once daily for 14 days
Study: NCT00634660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rAvPAL-PEG
Description: rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rAvPAL-PEG
Description: rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rAvPAL-PEG
Description: rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rAvPAL-PEG
Description: rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rAvPAL-PEG
Description: rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rAvPAL-PEG
Description: rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rAvPAL-PEG
Description: rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.
Study: NCT01832233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: The Symplicity Renal Denervation System is indicated for the delivery of low-level radiofrequency energy through the wall of the renal artery to denervate the kidney and reduce blood pressure in adult patients with refractory hypertension. The Symplicity Generator delivers controlled relatively low power radiofrequency energy (approximately 8 watts for 2 minutes). The Symplicity System selectively denervates the kidney by delivering radiofrequency from the generator via the electrode of the catheter through the renal artery wall from the intra-luminal side to ablate the renal sympathetic efferent and afferent nerves and reduce overall sympathetic nervous system activity.
Study: NCT00196404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-3001a
Description: 4mg daily vaginally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-3001b
Description: 6 mg vaginally daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered vaginally to match experimental arms
Study: NCT04626492

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative MRI imaging
Description: Dynamic contrast enhanced magnetic resonance imaging,Intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging,Iterative decomposition of water and fat with echo asymmetry and least squares estimation quantification sequence

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative MRI imaging
Description: Dynamic contrast enhanced magnetic resonance imaging,Intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging,Iterative decomposition of water and fat with echo asymmetry and least squares estimation quantification sequence

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative MRI imaging
Description: Dynamic contrast enhanced magnetic resonance imaging,Intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging,Iterative decomposition of water and fat with echo asymmetry and least squares estimation quantification sequence

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative MRI imaging
Description: Dynamic contrast enhanced magnetic resonance imaging,Intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging,Iterative decomposition of water and fat with echo asymmetry and least squares estimation quantification sequence

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative MRI imaging
Description: Dynamic contrast enhanced magnetic resonance imaging,Intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging,Iterative decomposition of water and fat with echo asymmetry and least squares estimation quantification sequence
Study: NCT01980550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sublingual nicotine
Description: The nicotine sublingual tablet is Smokers were recommended to use one or two tablets per hour, up to a maximum of 20 tablets per day. Subjects were advised to use the full treatment dose for 4 weeks. After this time-point, treatment could be tapered off up to the 8-week visit. During the next 4-week follow-up phase, no further medication was dispensed. Staff, who dispensed medications, were not involved in treating the subjects. During each patient visit, the importance of adequate dosing with study medication was emphasized. The medication was free of charge. In addition, all participants received six sessions of standardized behavioral group counseling focusing on self-monitoring and behavioral modification approaches.
Study: NCT02522455

Intervention type: OTHER
Group type: OTHER
Intervention: Flow-cycle ventilation
Description: Pressure support level set as per previous pressure requirements to deliver a tidal volume of 5ml/kg (the same pressure amount used as the peak inspiratory pressure in the time-cycled mode)

Intervention type: OTHER
Group type: OTHER
Intervention: Time-cycle ventilation mode
Description: Peak inspiratory pressure set to deliver 5ml/kg tidal volume, Rate set as per previous requirements
Study: NCT02853357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulation
Description: Middle Thoracic: Participants are placed in the supine position with their arms over their chest. The clinician rolls the participant to their side and places the fulcrum at the desired thoracic segment and the participant is rolled back onto the clinician's hand. The participant is instructed to take a deep breath. As the participant is exhaling, the clinician uses his body to push through the participant's arms to perform a high velocity thrust in an anterior to posterior directed force. Lower Thoracic: With the patient in a prone position, the clinician achieves a skin lock with both pisiforms over the transverse processes of the target vertebra. The clinician then uses his body to push down through his arms to perform a high-velocity, low-amplitude posterior to anterior thrust.
Study: NCT02242526

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parietex™ Composite Hiatal Mesh, North Haven, CT
Description: Parietex™ Composite Hiatal Mesh (North Haven, CT) designed for hiatal hernia repair.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biodesign™ Surgisis® Graft, Cook Medical, Bloomington
Description: Biodesign™ Surgisis® Graft (Cook Medical, Bloomington) designed for hiatal hernia repair.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biodesign™ Surgisis® Graft, Cook Medical, Bloomington
Description: Biodesign™ Surgisis® Graft (Cook Medical, Bloomington) designed for hiatal hernia repair.
Study: NCT02853357

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Manipulation
Description: The participants are positioned in prone and the clinician's hands are placed with the pisiforms of each hand over the transverse processes of the target vertebra. The clinician will only apply minimal pressure and slide the hands across the skin to mimic the manipulative thrust. This sham procedure has been shown to be an adequate sham comparator for spinal manipulative therapy (SMT) with similar expectations and believability as SMT active treatment

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Core Strengthening Exercises
Description: Both groups will receive the following exercises at each visit. The core strengthening (core strengthening) exercises are a standard protocol used by Richardson et al and Franca et al which are proposed to target muscles responsible for segmental stabilization, specifically the transverse abdominis (TrA) and the lumbar multifidi (LM). Exercises will include: TrA exercises in 4 point kneeling and in supine with flexed knee, LM exercises in prone, and co-contraction of TrA and LM in upright position. Three sets of 15 repetitions will be done for each exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Strengthening Exercises
Description: Both groups will receive the following exercises at each visit. The core strengthening (core strengthening) exercises are a standard protocol used by Richardson et al and Franca et al which are proposed to target muscles responsible for segmental stabilization, specifically the transverse abdominis (TrA) and the lumbar multifidi (LM). Exercises will include: TrA exercises in 4 point kneeling and in supine with flexed knee, LM exercises in prone, and co-contraction of TrA and LM in upright position. Three sets of 15 repetitions will be done for each exercise.
Study: NCT02319525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized patient decision-aid
Description: The decision-aid contained information regarding lupus and lupus nephritis, its impact on patient lives and benefits and harms of lupus nephritis treatments, focused on immunosuppressive medications compared to each other. The content of the decision-aid allowed individualization based on patient preference for details on certain aspects, as well as the desire to view additional, optional sections of the decision-aid.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (lupus pamphlet)
Description: Patient received the standard handout/pamphlet from a non-profit organization (American College of Rheumatology \[ACR\]) regarding lupus and its treatments, that explained risks and benefits of various treatments
Study: NCT03609853

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vapor (distilled water)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized THC, limonene, or THC and limonene
Description: Acute drug exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized THC, limonene, or THC and limonene
Description: Acute drug exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized THC, limonene, or THC and limonene
Description: Acute drug exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized THC, limonene, or THC and limonene
Description: Acute drug exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized THC, limonene, or THC and limonene
Description: Acute drug exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized THC, limonene, or THC and limonene
Description: Acute drug exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized THC, limonene, or THC and limonene
Description: Acute drug exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized THC, limonene, or THC and limonene
Description: Acute drug exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized THC, limonene, or THC and limonene
Description: Acute drug exposure
Study: NCT04246320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal directed therapy (GDT)
Description: Goal directed therapy (GDT) hemodynamic management (MAP \> 60 mmHg) and processed EEG-guided anesthesia (PSI targeted between 30-50).
Study: NCT00882427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced model predictive control algorithm (eMPC)
Description: eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
Study: NCT03754413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental
Description: Neuramis® Deep Lidocaine

Intervention type: DRUG
Group type: OTHER
Intervention: comparator
Description: No-treatment
Study: NCT04681547

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genicular nerve Block
Description: After the administration of spinal anesthesia, the anatomical structures of the proximal and distal region of the knee will be explored through an M- ultrasound machine Turbo® with a high-frequency 6-13 MHz linear probe.~The ultrasound transducer will be placed in a coronal orientation to the axis of the knee in the corresponding area to be blocked according to anatomical landmarks of superior medial genicular nerve (SMGN), inferior medial genicular nerve block (IMGN), superior lateral genicular nerve (SLGN), inferior lateral genicular nerve (ILGN), and recurrent genicular nerve (RGN).~It should be noted that the visualization of the genicular arteries in the femoral epicondyles and in the area of the tibial plateau, represents an accurate guide to where the sensory afferents are, however; its display is not constant.~4 ml of 0.2% ropivacaine will be administered, with adrenaline 1: 100 000 in each of the five nerves.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Infiltration Analgesia
Description: 100 ml of ropivacaine 0.2% with 1 mg of epinephrine during the period of intraoperative ischemia and, before the closure of the surgical wound, 50 ml of ropivacaine 0.2%.
Study: NCT01366495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Bridge
Description: Project Bridge provides intensive case management for individuals with HIV as they transition back into the community from incarceration. The primary goal of the program is to increase continuity of medical care through social stabilization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Bridge
Description: Project Bridge provides intensive case management for individuals with HIV as they transition back into the community from incarceration. The primary goal of the program is to increase continuity of medical care through social stabilization.
Study: NCT03475095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tuina
Description: Patients will receive Tuina therapies tiwce per week in one month.each time lasts about 20 minutes,a total of 4 weeks.
Study: NCT04196153

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pedicle screws instrumentation
Description: The screws are inserted in two or more consecutive levels to prevent motion at the segments that are being fused. It will be done using one of the two guidance technique depending on which arm the patient will be randomized to.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pedicle screws instrumentation
Description: The screws are inserted in two or more consecutive levels to prevent motion at the segments that are being fused. It will be done using one of the two guidance technique depending on which arm the patient will be randomized to.